Referencias

1. Batson OV. The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res 1995;312:4-9. http://www.ncbi.nlm.nih.gov/pubmed/7634616
2. Urwin GH, Percival RC, Harris S, et al. Generalized increase in bone resorption in carcinoma of the prostate. Br J Urol 1985;57:721-3.
3. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996;22:289-331.
4. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in out patients with metastatic cancer. N Engl J Med 1994;330:592-6.
5. Coleman RE. Management of bone metastases. The Oncologist 2000;5:463-70.
6. McEwan AJ. Palliation of bone pain. In: Ell PJ and Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd edition. Edinburgh: Churchill Livingstone 2004, pp 407-21.
7. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46: 38S-47S.
8. Shah Syed GM, Maken RN, Muzzaffar N, et al. Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun 1999;20:697-702.
9. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-22.
10. Maxon HR 3rd, Thomas SR, Hertzberg VS, et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 1992;22:33-40.
11. Quirijnen JM, Han SH, Zonnenberg BA, et al. Efficacy of rhenium-186-etidronate in prostatic cancer patients with metastatic bone pain. J Nucl Med 1996;37:1511-5.
12. De Klerk JM, Zonnenberg BA, van het Schip AD, et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21: 1114-1120.
13. Lam MG, de Klerk JM, van Rijk PP. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging 2004; 31 suppl 1: S162-S170.
14. Han SH, Zonnenberg BA, de Klerk JM, et al. 186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med 1999;40:639-42.
15. Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostare cancer skeletal metastases. Br J Cancer 2003; 89:525-629.
16. Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostare cancer skeletal metastases. Br J Cancer 2003; 89:525-629.
17. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21:2869-75.
18. Zhang H, Tian M, Li S, et al. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 2003;18:719-26.
19. Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989;15:784-95.
20. Resche I, Chatal JF, Peching A, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-91.
21. Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging 2004;31 suppl 1: S171-S178.
22. Srivastava SC, Atkins HL, Krishnamurthy GT et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res 1998;4:61-68.
23. Criteria for Palliation of Bone Metastases. TECDOC-1549. IAEA, Vienna, 2007. http://www-pub.iaea.org/MTCD/publications/PDF/te_1549_web.pdf.
24. Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934-40.
25. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-22.
26. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400.
27. Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 1999;40:256-61.
28. Liepe K, Franke WG, Kropp J, et al. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin 2000;39:146-151.
29. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007;109:637-43.
30. Kvols LK. Radiation sensitizers: A selective review of molecules targeting DNA and non-DNA targets. J Nucl Med 2005;46 (suppl 1):187S-190S.
31. Tu S-M, Delpassand ES, Jones D, et al. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol 1997;2:191-7.
32. Tu S-M, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001;357/9253:336-41.
33. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial. J Nucl Med 2002;43:79-86.
34. Pagliaro LC, Delpassand ES, Williams D, et al. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003; 97:2988-94.
35. Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med 2005;35:152-8.